No Cover Image

Book chapter 267 views

Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis

Shane Heffernan Orcid Logo, Gill Conway Orcid Logo

Pain Management - Practices, Novel Therapies and Bioactives

Swansea University Authors: Shane Heffernan Orcid Logo, Gill Conway Orcid Logo

Full text not available from this repository: check for access using links below.

DOI (Published version): 10.5772/intechopen.95919

Abstract

Chronic pain is a considerable health concern worldwide, effecting almost 30% of all European adults. Osteoarthritis (OA), a progressive pro-inflammatory condition, is one of the leading causes of chronic pain (effecting 13% of all those over 50 years, globally) and is the most common cause of join...

Full description

Published in: Pain Management - Practices, Novel Therapies and Bioactives
ISBN: 9781838800260 9781838808976
Published: IntechOpen 2021
URI: https://cronfa.swan.ac.uk/Record/cronfa65436
first_indexed 2024-03-23T12:43:49Z
last_indexed 2024-11-25T14:16:04Z
id cronfa65436
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2024-03-23T12:43:58.1567407</datestamp><bib-version>v2</bib-version><id>65436</id><entry>2024-01-10</entry><title>Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis</title><swanseaauthors><author><sid>72c0b36891dfbec0378c0d0f7916e807</sid><ORCID>0000-0002-3297-9335</ORCID><firstname>Shane</firstname><surname>Heffernan</surname><name>Shane Heffernan</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>e33e0ee5a076ad91fe6615117caa1800</sid><ORCID>0000-0002-5991-0960</ORCID><firstname>Gill</firstname><surname>Conway</surname><name>Gill Conway</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-01-10</date><deptcode>EAAS</deptcode><abstract>Chronic pain is a considerable health concern worldwide, effecting almost 30% of all European adults. Osteoarthritis (OA), a progressive pro-inflammatory condition, is one of the leading causes of chronic pain (effecting 13% of all &#xFEFF;those over 50 years, globally) and is the most common cause of joint pain. The prevalence of non-steroidal anti-inflammatory drug (NSAIDs) and analgesic use has been well studied and is abundant throughout the western world, with women being the greatest users and ibuprofen generally being the most &#xFEFF;reported NSAID. In the US, 65% of all OA patients are prescribed NSAIDs for pain management and form part of the current recommended strategy for OA clinical management. While some NSAIDs and analgesics are effective at improving pain and physical function, they come with significant and harmful side effects such as gastrointestinal complications, renal disturbances and severe cardiovascular events. Given these side-effects, any reduction in NSAID and analgesia use (and the resulting potentially harmful side effects) is of particular importance to OA public health. As such, a number of non-pharmaceutical alternatives (bioactive nutraceuticals) have been developed that may reduce NSAID and analgesia use while maintaining pain reduction and improvements in physical function. This chapter will discuss select nutraceuticals that are not currently in mainstream use but may have the potential to aid in the treatment of OA.</abstract><type>Book chapter</type><journal>Pain Management - Practices, Novel Therapies and Bioactives</journal><volume/><journalNumber/><paginationStart/><paginationEnd/><publisher>IntechOpen</publisher><placeOfPublication/><isbnPrint>9781838800260</isbnPrint><isbnElectronic>9781838808976</isbnElectronic><issnPrint/><issnElectronic/><keywords>joint pain; pain medication; non-pharmacological pain management; mechanisms of pain and action; paracetamol (acetaminophenN-acetyl-p-aminophenol; APAP); opioids</keywords><publishedDay>1</publishedDay><publishedMonth>3</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-03-01</publishedDate><doi>10.5772/intechopen.95919</doi><url/><notes/><college>COLLEGE NANME</college><department>Engineering and Applied Sciences School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>EAAS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2024-03-23T12:43:58.1567407</lastEdited><Created>2024-01-10T15:28:11.5738291</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Shane</firstname><surname>Heffernan</surname><orcid>0000-0002-3297-9335</orcid><order>1</order></author><author><firstname>Gill</firstname><surname>Conway</surname><orcid>0000-0002-5991-0960</orcid><order>2</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling 2024-03-23T12:43:58.1567407 v2 65436 2024-01-10 Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis 72c0b36891dfbec0378c0d0f7916e807 0000-0002-3297-9335 Shane Heffernan Shane Heffernan true false e33e0ee5a076ad91fe6615117caa1800 0000-0002-5991-0960 Gill Conway Gill Conway true false 2024-01-10 EAAS Chronic pain is a considerable health concern worldwide, effecting almost 30% of all European adults. Osteoarthritis (OA), a progressive pro-inflammatory condition, is one of the leading causes of chronic pain (effecting 13% of all those over 50 years, globally) and is the most common cause of joint pain. The prevalence of non-steroidal anti-inflammatory drug (NSAIDs) and analgesic use has been well studied and is abundant throughout the western world, with women being the greatest users and ibuprofen generally being the most reported NSAID. In the US, 65% of all OA patients are prescribed NSAIDs for pain management and form part of the current recommended strategy for OA clinical management. While some NSAIDs and analgesics are effective at improving pain and physical function, they come with significant and harmful side effects such as gastrointestinal complications, renal disturbances and severe cardiovascular events. Given these side-effects, any reduction in NSAID and analgesia use (and the resulting potentially harmful side effects) is of particular importance to OA public health. As such, a number of non-pharmaceutical alternatives (bioactive nutraceuticals) have been developed that may reduce NSAID and analgesia use while maintaining pain reduction and improvements in physical function. This chapter will discuss select nutraceuticals that are not currently in mainstream use but may have the potential to aid in the treatment of OA. Book chapter Pain Management - Practices, Novel Therapies and Bioactives IntechOpen 9781838800260 9781838808976 joint pain; pain medication; non-pharmacological pain management; mechanisms of pain and action; paracetamol (acetaminophenN-acetyl-p-aminophenol; APAP); opioids 1 3 2021 2021-03-01 10.5772/intechopen.95919 COLLEGE NANME Engineering and Applied Sciences School COLLEGE CODE EAAS Swansea University 2024-03-23T12:43:58.1567407 2024-01-10T15:28:11.5738291 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Shane Heffernan 0000-0002-3297-9335 1 Gill Conway 0000-0002-5991-0960 2
title Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis
spellingShingle Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis
Shane Heffernan
Gill Conway
title_short Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis
title_full Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis
title_fullStr Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis
title_full_unstemmed Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis
title_sort Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis
author_id_str_mv 72c0b36891dfbec0378c0d0f7916e807
e33e0ee5a076ad91fe6615117caa1800
author_id_fullname_str_mv 72c0b36891dfbec0378c0d0f7916e807_***_Shane Heffernan
e33e0ee5a076ad91fe6615117caa1800_***_Gill Conway
author Shane Heffernan
Gill Conway
author2 Shane Heffernan
Gill Conway
format Book chapter
container_title Pain Management - Practices, Novel Therapies and Bioactives
publishDate 2021
institution Swansea University
isbn 9781838800260
9781838808976
doi_str_mv 10.5772/intechopen.95919
publisher IntechOpen
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 0
active_str 0
description Chronic pain is a considerable health concern worldwide, effecting almost 30% of all European adults. Osteoarthritis (OA), a progressive pro-inflammatory condition, is one of the leading causes of chronic pain (effecting 13% of all those over 50 years, globally) and is the most common cause of joint pain. The prevalence of non-steroidal anti-inflammatory drug (NSAIDs) and analgesic use has been well studied and is abundant throughout the western world, with women being the greatest users and ibuprofen generally being the most reported NSAID. In the US, 65% of all OA patients are prescribed NSAIDs for pain management and form part of the current recommended strategy for OA clinical management. While some NSAIDs and analgesics are effective at improving pain and physical function, they come with significant and harmful side effects such as gastrointestinal complications, renal disturbances and severe cardiovascular events. Given these side-effects, any reduction in NSAID and analgesia use (and the resulting potentially harmful side effects) is of particular importance to OA public health. As such, a number of non-pharmaceutical alternatives (bioactive nutraceuticals) have been developed that may reduce NSAID and analgesia use while maintaining pain reduction and improvements in physical function. This chapter will discuss select nutraceuticals that are not currently in mainstream use but may have the potential to aid in the treatment of OA.
published_date 2021-03-01T20:27:50Z
_version_ 1821348064636436480
score 11.04748

Similar Items